nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Vismodegib—SMO—pancreatitis	0.0176	0.908	CrCbGaD
Sorafenib—ABCC2—bile duct—pancreatitis	0.017	0.0702	CbGeAlD
Sorafenib—ABCC2—bile—pancreatitis	0.0131	0.0539	CbGeAlD
Sorafenib—HIPK3—islet of Langerhans—pancreatitis	0.00702	0.029	CbGeAlD
Sorafenib—Haemoglobin decreased—Hyoscyamine—pancreatitis	0.00677	0.0495	CcSEcCtD
Sorafenib—PDGFRA—gall bladder—pancreatitis	0.00603	0.0249	CbGeAlD
Sorafenib—KIT—exocrine gland—pancreatitis	0.00573	0.0236	CbGeAlD
Sorafenib—Dysphagia—Propantheline—pancreatitis	0.00571	0.0418	CcSEcCtD
Sorafenib—Erectile dysfunction—Propantheline—pancreatitis	0.00526	0.0385	CcSEcCtD
Sorafenib—Gastrooesophageal reflux disease—Hyoscyamine—pancreatitis	0.00516	0.0377	CcSEcCtD
Sorafenib—HIPK3—pancreas—pancreatitis	0.00494	0.0204	CbGeAlD
Sorafenib—MKNK2—islet of Langerhans—pancreatitis	0.00491	0.0203	CbGeAlD
Sorafenib—KIT—gall bladder—pancreatitis	0.00482	0.0199	CbGeAlD
Sorafenib—TAOK2—blood—pancreatitis	0.00471	0.0194	CbGeAlD
Sorafenib—PDGFRB—gall bladder—pancreatitis	0.00471	0.0194	CbGeAlD
Sorafenib—Blood pressure increased—Hyoscyamine—pancreatitis	0.00466	0.0341	CcSEcCtD
Sorafenib—Skin exfoliation—Hyoscyamine—pancreatitis	0.00445	0.0325	CcSEcCtD
Sorafenib—RALBP1—islet of Langerhans—pancreatitis	0.00443	0.0183	CbGeAlD
Sorafenib—ZAK—digestive system—pancreatitis	0.00431	0.0178	CbGeAlD
Sorafenib—Flushing—Propantheline—pancreatitis	0.00424	0.031	CcSEcCtD
Sorafenib—FLT1—islet of Langerhans—pancreatitis	0.00422	0.0174	CbGeAlD
Sorafenib—HIPK3—digestive system—pancreatitis	0.00422	0.0174	CbGeAlD
Sorafenib—RAF1—islet of Langerhans—pancreatitis	0.00419	0.0173	CbGeAlD
Sorafenib—EPHB6—islet of Langerhans—pancreatitis	0.00417	0.0172	CbGeAlD
Sorafenib—ZAK—blood—pancreatitis	0.0041	0.0169	CbGeAlD
Sorafenib—HIPK3—blood—pancreatitis	0.00402	0.0166	CbGeAlD
Sorafenib—Eczema—Hyoscyamine—pancreatitis	0.00376	0.0275	CcSEcCtD
Sorafenib—BRAF—blood—pancreatitis	0.0036	0.0148	CbGeAlD
Sorafenib—MKNK2—pancreas—pancreatitis	0.00345	0.0142	CbGeAlD
Sorafenib—EPHX2—blood—pancreatitis	0.00344	0.0142	CbGeAlD
Sorafenib—FLT3—blood—pancreatitis	0.00342	0.0141	CbGeAlD
Sorafenib—Hyponatraemia—Hyoscyamine—pancreatitis	0.00339	0.0248	CcSEcCtD
Sorafenib—Dry mouth—Propantheline—pancreatitis	0.00331	0.0242	CcSEcCtD
Sorafenib—UGT1A9—digestive system—pancreatitis	0.0033	0.0136	CbGeAlD
Sorafenib—Anaphylactic shock—Propantheline—pancreatitis	0.00325	0.0237	CcSEcCtD
Sorafenib—Dehydration—Hyoscyamine—pancreatitis	0.00314	0.023	CcSEcCtD
Sorafenib—RALBP1—pancreas—pancreatitis	0.00312	0.0129	CbGeAlD
Sorafenib—FLT4—blood—pancreatitis	0.0031	0.0128	CbGeAlD
Sorafenib—Dry skin—Hyoscyamine—pancreatitis	0.0031	0.0227	CcSEcCtD
Sorafenib—PDGFRB—islet of Langerhans—pancreatitis	0.00309	0.0127	CbGeAlD
Sorafenib—Hypokalaemia—Hyoscyamine—pancreatitis	0.00308	0.0225	CcSEcCtD
Sorafenib—FLT1—pancreas—pancreatitis	0.00296	0.0122	CbGeAlD
Sorafenib—MKNK2—digestive system—pancreatitis	0.00295	0.0122	CbGeAlD
Sorafenib—RAF1—pancreas—pancreatitis	0.00295	0.0122	CbGeAlD
Sorafenib—Dysphagia—Hyoscyamine—pancreatitis	0.00292	0.0214	CcSEcCtD
Sorafenib—MKNK1—digestive system—pancreatitis	0.00291	0.012	CbGeAlD
Sorafenib—MAP3K7—blood—pancreatitis	0.0029	0.012	CbGeAlD
Sorafenib—RET—digestive system—pancreatitis	0.00287	0.0119	CbGeAlD
Sorafenib—MKNK2—blood—pancreatitis	0.00281	0.0116	CbGeAlD
Sorafenib—Constipation—Propantheline—pancreatitis	0.00278	0.0203	CcSEcCtD
Sorafenib—MKNK1—blood—pancreatitis	0.00277	0.0114	CbGeAlD
Sorafenib—RET—blood—pancreatitis	0.00274	0.0113	CbGeAlD
Sorafenib—Erectile dysfunction—Hyoscyamine—pancreatitis	0.00269	0.0197	CcSEcCtD
Sorafenib—RALBP1—digestive system—pancreatitis	0.00266	0.011	CbGeAlD
Sorafenib—Urticaria—Propantheline—pancreatitis	0.00258	0.0189	CcSEcCtD
Sorafenib—Acute coronary syndrome—Hyoscyamine—pancreatitis	0.00257	0.0188	CcSEcCtD
Sorafenib—Myocardial infarction—Hyoscyamine—pancreatitis	0.00255	0.0187	CcSEcCtD
Sorafenib—RALBP1—blood—pancreatitis	0.00254	0.0105	CbGeAlD
Sorafenib—FLT1—digestive system—pancreatitis	0.00253	0.0104	CbGeAlD
Sorafenib—RAF1—digestive system—pancreatitis	0.00252	0.0104	CbGeAlD
Sorafenib—FLT1—blood—pancreatitis	0.00241	0.00995	CbGeAlD
Sorafenib—RAF1—blood—pancreatitis	0.0024	0.00989	CbGeAlD
Sorafenib—STK10—digestive system—pancreatitis	0.0024	0.00989	CbGeAlD
Sorafenib—Hypersensitivity—Propantheline—pancreatitis	0.00239	0.0175	CcSEcCtD
Sorafenib—EPHB6—blood—pancreatitis	0.00238	0.00984	CbGeAlD
Sorafenib—PDGFRA—digestive system—pancreatitis	0.00237	0.00979	CbGeAlD
Sorafenib—Asthenia—Propantheline—pancreatitis	0.00233	0.017	CcSEcCtD
Sorafenib—STK10—blood—pancreatitis	0.00228	0.00942	CbGeAlD
Sorafenib—UGT1A1—digestive system—pancreatitis	0.00226	0.00934	CbGeAlD
Sorafenib—PDGFRA—blood—pancreatitis	0.00226	0.00932	CbGeAlD
Sorafenib—KIT—pancreas—pancreatitis	0.00222	0.00916	CbGeAlD
Sorafenib—Flushing—Hyoscyamine—pancreatitis	0.00217	0.0159	CcSEcCtD
Sorafenib—PDGFRB—pancreas—pancreatitis	0.00217	0.00895	CbGeAlD
Sorafenib—UGT1A1—blood—pancreatitis	0.00216	0.0089	CbGeAlD
Sorafenib—Dizziness—Propantheline—pancreatitis	0.00215	0.0157	CcSEcCtD
Sorafenib—KDR—digestive system—pancreatitis	0.00214	0.00883	CbGeAlD
Sorafenib—Arrhythmia—Hyoscyamine—pancreatitis	0.00209	0.0153	CcSEcCtD
Sorafenib—CSF1R—digestive system—pancreatitis	0.00209	0.00862	CbGeAlD
Sorafenib—Vomiting—Propantheline—pancreatitis	0.00206	0.0151	CcSEcCtD
Sorafenib—Mental disorder—Hyoscyamine—pancreatitis	0.00205	0.015	CcSEcCtD
Sorafenib—Rash—Propantheline—pancreatitis	0.00205	0.015	CcSEcCtD
Sorafenib—Dermatitis—Propantheline—pancreatitis	0.00204	0.015	CcSEcCtD
Sorafenib—KDR—blood—pancreatitis	0.00204	0.00841	CbGeAlD
Sorafenib—MAP2K5—blood—pancreatitis	0.00204	0.00841	CbGeAlD
Sorafenib—Erythema—Hyoscyamine—pancreatitis	0.00204	0.0149	CcSEcCtD
Sorafenib—Headache—Propantheline—pancreatitis	0.00203	0.0149	CcSEcCtD
Sorafenib—Dysgeusia—Hyoscyamine—pancreatitis	0.00199	0.0146	CcSEcCtD
Sorafenib—CSF1R—blood—pancreatitis	0.00199	0.00821	CbGeAlD
Sorafenib—Nausea—Propantheline—pancreatitis	0.00193	0.0141	CcSEcCtD
Sorafenib—KIT—digestive system—pancreatitis	0.0019	0.00782	CbGeAlD
Sorafenib—Angioedema—Hyoscyamine—pancreatitis	0.00186	0.0136	CcSEcCtD
Sorafenib—PDGFRB—digestive system—pancreatitis	0.00185	0.00764	CbGeAlD
Sorafenib—Syncope—Hyoscyamine—pancreatitis	0.00183	0.0134	CcSEcCtD
Sorafenib—KIT—blood—pancreatitis	0.00181	0.00745	CbGeAlD
Sorafenib—Loss of consciousness—Hyoscyamine—pancreatitis	0.00179	0.0131	CcSEcCtD
Sorafenib—Vismodegib—ALB—pancreatitis	0.00179	0.0924	CrCbGaD
Sorafenib—PDGFRB—blood—pancreatitis	0.00176	0.00728	CbGeAlD
Sorafenib—ABCC4—pancreas—pancreatitis	0.00173	0.00712	CbGeAlD
Sorafenib—Dry mouth—Hyoscyamine—pancreatitis	0.0017	0.0124	CcSEcCtD
Sorafenib—Anaphylactic shock—Hyoscyamine—pancreatitis	0.00166	0.0122	CcSEcCtD
Sorafenib—Shock—Hyoscyamine—pancreatitis	0.00163	0.012	CcSEcCtD
Sorafenib—CYP3A5—islet of Langerhans—pancreatitis	0.00161	0.00664	CbGeAlD
Sorafenib—Dyspnoea—Hyoscyamine—pancreatitis	0.00148	0.0108	CcSEcCtD
Sorafenib—ABCC4—digestive system—pancreatitis	0.00147	0.00608	CbGeAlD
Sorafenib—HTR2B—digestive system—pancreatitis	0.00147	0.00605	CbGeAlD
Sorafenib—Dyspepsia—Hyoscyamine—pancreatitis	0.00146	0.0107	CcSEcCtD
Sorafenib—Fatigue—Hyoscyamine—pancreatitis	0.00143	0.0105	CcSEcCtD
Sorafenib—ABCC2—digestive system—pancreatitis	0.00143	0.00589	CbGeAlD
Sorafenib—Constipation—Hyoscyamine—pancreatitis	0.00142	0.0104	CcSEcCtD
Sorafenib—Pain—Hyoscyamine—pancreatitis	0.00142	0.0104	CcSEcCtD
Sorafenib—ABCC4—blood—pancreatitis	0.00141	0.0058	CbGeAlD
Sorafenib—HTR2B—blood—pancreatitis	0.0014	0.00577	CbGeAlD
Sorafenib—ABCC2—blood—pancreatitis	0.00136	0.00561	CbGeAlD
Sorafenib—Gastrointestinal pain—Hyoscyamine—pancreatitis	0.00136	0.00994	CcSEcCtD
Sorafenib—Urticaria—Hyoscyamine—pancreatitis	0.00132	0.00966	CcSEcCtD
Sorafenib—Abdominal pain—Hyoscyamine—pancreatitis	0.00131	0.00961	CcSEcCtD
Sorafenib—Body temperature increased—Hyoscyamine—pancreatitis	0.00131	0.00961	CcSEcCtD
Sorafenib—CYP2C19—digestive system—pancreatitis	0.00123	0.00506	CbGeAlD
Sorafenib—Hypersensitivity—Hyoscyamine—pancreatitis	0.00122	0.00896	CcSEcCtD
Sorafenib—Asthenia—Hyoscyamine—pancreatitis	0.00119	0.00872	CcSEcCtD
Sorafenib—Pruritus—Hyoscyamine—pancreatitis	0.00118	0.0086	CcSEcCtD
Sorafenib—CYP2C19—blood—pancreatitis	0.00117	0.00482	CbGeAlD
Sorafenib—Diarrhoea—Hyoscyamine—pancreatitis	0.00114	0.00832	CcSEcCtD
Sorafenib—CYP3A5—pancreas—pancreatitis	0.00113	0.00467	CbGeAlD
Sorafenib—Dizziness—Hyoscyamine—pancreatitis	0.0011	0.00804	CcSEcCtD
Sorafenib—Vomiting—Hyoscyamine—pancreatitis	0.00106	0.00773	CcSEcCtD
Sorafenib—Rash—Hyoscyamine—pancreatitis	0.00105	0.00767	CcSEcCtD
Sorafenib—Dermatitis—Hyoscyamine—pancreatitis	0.00105	0.00766	CcSEcCtD
Sorafenib—Headache—Hyoscyamine—pancreatitis	0.00104	0.00762	CcSEcCtD
Sorafenib—CYP2C8—blood—pancreatitis	0.00102	0.00421	CbGeAlD
Sorafenib—CYP1A2—digestive system—pancreatitis	0.001	0.00413	CbGeAlD
Sorafenib—ABCG2—blood—pancreatitis	0.000992	0.00409	CbGeAlD
Sorafenib—Nausea—Hyoscyamine—pancreatitis	0.000987	0.00722	CcSEcCtD
Sorafenib—CYP3A5—digestive system—pancreatitis	0.000966	0.00399	CbGeAlD
Sorafenib—CYP2B6—digestive system—pancreatitis	0.000961	0.00396	CbGeAlD
Sorafenib—CYP1A2—blood—pancreatitis	0.000955	0.00394	CbGeAlD
Sorafenib—CYP2C9—digestive system—pancreatitis	0.000951	0.00392	CbGeAlD
Sorafenib—CYP3A5—blood—pancreatitis	0.000921	0.0038	CbGeAlD
Sorafenib—CYP2B6—blood—pancreatitis	0.000915	0.00378	CbGeAlD
Sorafenib—CYP2C9—blood—pancreatitis	0.000906	0.00374	CbGeAlD
Sorafenib—ABCB1—islet of Langerhans—pancreatitis	0.000855	0.00353	CbGeAlD
Sorafenib—CYP3A4—digestive system—pancreatitis	0.000725	0.00299	CbGeAlD
Sorafenib—CYP2D6—digestive system—pancreatitis	0.000714	0.00294	CbGeAlD
Sorafenib—CYP3A4—blood—pancreatitis	0.000691	0.00285	CbGeAlD
Sorafenib—CYP2D6—blood—pancreatitis	0.00068	0.00281	CbGeAlD
Sorafenib—ABCB1—pancreas—pancreatitis	0.000601	0.00248	CbGeAlD
Sorafenib—ABCB1—digestive system—pancreatitis	0.000513	0.00212	CbGeAlD
Sorafenib—ABCB1—blood—pancreatitis	0.000489	0.00202	CbGeAlD
Sorafenib—CYP1A2—Metabolism—PLA2G1B—pancreatitis	1.53e-05	2.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.52e-05	2.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MDM2—pancreatitis	1.52e-05	2.52e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—pancreatitis	1.5e-05	2.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—LEP—pancreatitis	1.49e-05	2.48e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	1.49e-05	2.47e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—pancreatitis	1.49e-05	2.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—pancreatitis	1.49e-05	2.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—pancreatitis	1.48e-05	2.46e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADH1B—pancreatitis	1.48e-05	2.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—A2M—pancreatitis	1.48e-05	2.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—pancreatitis	1.47e-05	2.45e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GCG—pancreatitis	1.47e-05	2.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—pancreatitis	1.46e-05	2.43e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—pancreatitis	1.46e-05	2.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—pancreatitis	1.45e-05	2.41e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—pancreatitis	1.45e-05	2.41e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—pancreatitis	1.44e-05	2.4e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—pancreatitis	1.44e-05	2.39e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—pancreatitis	1.44e-05	2.39e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—pancreatitis	1.43e-05	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—INS—pancreatitis	1.43e-05	2.38e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—pancreatitis	1.42e-05	2.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—pancreatitis	1.42e-05	2.36e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—pancreatitis	1.42e-05	2.35e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—KRAS—pancreatitis	1.41e-05	2.35e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—pancreatitis	1.41e-05	2.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—pancreatitis	1.41e-05	2.34e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MDM2—pancreatitis	1.4e-05	2.32e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MDM2—pancreatitis	1.4e-05	2.32e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—KRAS—pancreatitis	1.39e-05	2.32e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KRAS—pancreatitis	1.39e-05	2.32e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—pancreatitis	1.39e-05	2.31e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—pancreatitis	1.39e-05	2.31e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—pancreatitis	1.39e-05	2.3e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CASP3—pancreatitis	1.39e-05	2.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.38e-05	2.3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—pancreatitis	1.38e-05	2.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CASP3—pancreatitis	1.37e-05	2.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—INS—pancreatitis	1.37e-05	2.27e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—LPL—pancreatitis	1.36e-05	2.27e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARG—pancreatitis	1.36e-05	2.26e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—pancreatitis	1.35e-05	2.25e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALDH2—pancreatitis	1.35e-05	2.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—pancreatitis	1.35e-05	2.24e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARG—pancreatitis	1.35e-05	2.24e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—pancreatitis	1.34e-05	2.23e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—LPL—pancreatitis	1.33e-05	2.21e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—INS—pancreatitis	1.33e-05	2.21e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	1.33e-05	2.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MDM2—pancreatitis	1.33e-05	2.2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KRAS—pancreatitis	1.32e-05	2.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MDM2—pancreatitis	1.32e-05	2.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KRAS—pancreatitis	1.32e-05	2.19e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—INS—pancreatitis	1.32e-05	2.19e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—pancreatitis	1.32e-05	2.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—pancreatitis	1.32e-05	2.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	1.32e-05	2.19e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—pancreatitis	1.31e-05	2.19e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GCG—pancreatitis	1.31e-05	2.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—pancreatitis	1.31e-05	2.17e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—pancreatitis	1.31e-05	2.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LEP—pancreatitis	1.29e-05	2.14e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—pancreatitis	1.29e-05	2.14e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—KRAS—pancreatitis	1.29e-05	2.14e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GCG—pancreatitis	1.28e-05	2.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—INS—pancreatitis	1.28e-05	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—pancreatitis	1.28e-05	2.12e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—pancreatitis	1.26e-05	2.09e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—pancreatitis	1.26e-05	2.09e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—pancreatitis	1.26e-05	2.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—pancreatitis	1.26e-05	2.09e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—pancreatitis	1.26e-05	2.09e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—pancreatitis	1.25e-05	2.08e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CASP3—pancreatitis	1.25e-05	2.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—KRAS—pancreatitis	1.24e-05	2.06e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—pancreatitis	1.24e-05	2.06e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—pancreatitis	1.24e-05	2.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—pancreatitis	1.23e-05	2.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KRAS—pancreatitis	1.22e-05	2.03e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—pancreatitis	1.22e-05	2.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KRAS—pancreatitis	1.22e-05	2.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	1.21e-05	2.01e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—pancreatitis	1.21e-05	2.01e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GCG—pancreatitis	1.21e-05	2.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—pancreatitis	1.2e-05	2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GCG—pancreatitis	1.2e-05	1.99e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—pancreatitis	1.19e-05	1.98e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MDM2—pancreatitis	1.19e-05	1.98e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—pancreatitis	1.19e-05	1.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—pancreatitis	1.19e-05	1.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—pancreatitis	1.19e-05	1.97e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—pancreatitis	1.19e-05	1.97e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—pancreatitis	1.19e-05	1.97e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—pancreatitis	1.18e-05	1.97e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.18e-05	1.97e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLA2G1B—pancreatitis	1.18e-05	1.96e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—pancreatitis	1.16e-05	1.93e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—pancreatitis	1.16e-05	1.93e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—pancreatitis	1.16e-05	1.93e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—pancreatitis	1.16e-05	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—LPL—pancreatitis	1.15e-05	1.92e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—pancreatitis	1.15e-05	1.91e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—pancreatitis	1.15e-05	1.91e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—A2M—pancreatitis	1.14e-05	1.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—pancreatitis	1.14e-05	1.89e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MDM2—pancreatitis	1.14e-05	1.89e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—pancreatitis	1.13e-05	1.89e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—pancreatitis	1.13e-05	1.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—pancreatitis	1.13e-05	1.87e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—pancreatitis	1.12e-05	1.87e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—pancreatitis	1.11e-05	1.85e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INS—pancreatitis	1.1e-05	1.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—pancreatitis	1.1e-05	1.83e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—pancreatitis	1.09e-05	1.82e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—pancreatitis	1.08e-05	1.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—pancreatitis	1.08e-05	1.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—pancreatitis	1.08e-05	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—pancreatitis	1.07e-05	1.79e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—pancreatitis	1.07e-05	1.78e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—pancreatitis	1.07e-05	1.77e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—pancreatitis	1.07e-05	1.77e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—pancreatitis	1.06e-05	1.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MDM2—pancreatitis	1.06e-05	1.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—pancreatitis	1.06e-05	1.76e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—pancreatitis	1.06e-05	1.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—pancreatitis	1.06e-05	1.76e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—pancreatitis	1.06e-05	1.75e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—pancreatitis	1.05e-05	1.74e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—pancreatitis	1.05e-05	1.74e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—pancreatitis	1.05e-05	1.74e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALDH2—pancreatitis	1.04e-05	1.73e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—pancreatitis	1.04e-05	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—pancreatitis	1.04e-05	1.72e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	1.03e-05	1.72e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—LPL—pancreatitis	1.03e-05	1.71e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GCG—pancreatitis	1.02e-05	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—pancreatitis	1.02e-05	1.69e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—pancreatitis	1.01e-05	1.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—pancreatitis	1.01e-05	1.68e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—pancreatitis	1.01e-05	1.68e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LPL—pancreatitis	1e-05	1.67e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—pancreatitis	1e-05	1.66e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—pancreatitis	1e-05	1.66e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—pancreatitis	9.95e-06	1.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—pancreatitis	9.94e-06	1.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—pancreatitis	9.94e-06	1.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—pancreatitis	9.93e-06	1.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—pancreatitis	9.92e-06	1.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—pancreatitis	9.92e-06	1.65e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—pancreatitis	9.91e-06	1.65e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—pancreatitis	9.88e-06	1.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—pancreatitis	9.86e-06	1.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—pancreatitis	9.79e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—pancreatitis	9.76e-06	1.62e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—pancreatitis	9.74e-06	1.62e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—pancreatitis	9.74e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—pancreatitis	9.72e-06	1.62e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—pancreatitis	9.71e-06	1.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—pancreatitis	9.68e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—pancreatitis	9.54e-06	1.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—pancreatitis	9.5e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—pancreatitis	9.47e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—pancreatitis	9.46e-06	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—pancreatitis	9.44e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—pancreatitis	9.39e-06	1.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—pancreatitis	9.33e-06	1.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—pancreatitis	9.24e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—pancreatitis	9.22e-06	1.53e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MDM2—pancreatitis	9.16e-06	1.52e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—pancreatitis	9.02e-06	1.5e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—pancreatitis	9.02e-06	1.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—pancreatitis	9.01e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—pancreatitis	8.95e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—pancreatitis	8.93e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—pancreatitis	8.93e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—pancreatitis	8.74e-06	1.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—pancreatitis	8.62e-06	1.43e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—pancreatitis	8.57e-06	1.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—pancreatitis	8.56e-06	1.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—pancreatitis	8.54e-06	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—pancreatitis	8.52e-06	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—pancreatitis	8.51e-06	1.42e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—pancreatitis	8.5e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—pancreatitis	8.42e-06	1.4e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—pancreatitis	8.42e-06	1.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—pancreatitis	8.32e-06	1.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—pancreatitis	8.3e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—pancreatitis	8.26e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—pancreatitis	8.2e-06	1.36e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—pancreatitis	8.15e-06	1.35e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—pancreatitis	8.14e-06	1.35e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—pancreatitis	8.06e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—pancreatitis	8.02e-06	1.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—pancreatitis	7.96e-06	1.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—pancreatitis	7.96e-06	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—pancreatitis	7.92e-06	1.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCG—pancreatitis	7.89e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—pancreatitis	7.83e-06	1.3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—pancreatitis	7.69e-06	1.28e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—pancreatitis	7.66e-06	1.27e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—pancreatitis	7.66e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—pancreatitis	7.65e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—pancreatitis	7.57e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—pancreatitis	7.52e-06	1.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—pancreatitis	7.4e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—pancreatitis	7.37e-06	1.23e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—pancreatitis	7.34e-06	1.22e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—pancreatitis	7.34e-06	1.22e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—pancreatitis	7.34e-06	1.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—pancreatitis	7.33e-06	1.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—pancreatitis	7.27e-06	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—pancreatitis	7.26e-06	1.21e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—pancreatitis	7.2e-06	1.2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—pancreatitis	6.96e-06	1.16e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—pancreatitis	6.94e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—pancreatitis	6.91e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—pancreatitis	6.87e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—pancreatitis	6.85e-06	1.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—pancreatitis	6.85e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—pancreatitis	6.78e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—pancreatitis	6.76e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—pancreatitis	6.72e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—pancreatitis	6.63e-06	1.1e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—pancreatitis	6.6e-06	1.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—pancreatitis	6.54e-06	1.09e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—pancreatitis	6.39e-06	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—pancreatitis	6.26e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—pancreatitis	6.23e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—pancreatitis	6.22e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—pancreatitis	6.19e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—pancreatitis	6.16e-06	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—pancreatitis	5.97e-06	9.92e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—pancreatitis	5.92e-06	9.83e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—pancreatitis	5.91e-06	9.83e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—pancreatitis	5.86e-06	9.74e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—pancreatitis	5.83e-06	9.68e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—pancreatitis	5.77e-06	9.6e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—pancreatitis	5.75e-06	9.55e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—pancreatitis	5.58e-06	9.27e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—pancreatitis	5.44e-06	9.04e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—pancreatitis	5.39e-06	8.96e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—pancreatitis	5.27e-06	8.76e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—pancreatitis	5.03e-06	8.36e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—pancreatitis	4.81e-06	8e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—pancreatitis	4.61e-06	7.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—pancreatitis	4.52e-06	7.51e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—pancreatitis	4.43e-06	7.37e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—pancreatitis	4.06e-06	6.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—pancreatitis	3.56e-06	5.91e-06	CbGpPWpGaD
